# Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

> **NCT05019690** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Advanced Triple Negative Breast Cancer

## Interventions

- **DRUG:** Apatinib Mesylate
- **DRUG:** Albumin-Bound Paclitaxel

## Key facts

- **NCT ID:** NCT05019690
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05019690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05019690, "Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05019690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*